ADCT
ADC Therapeutics SACompany Information
- Company Name
- ADC Therapeutics SA
- CIK
- CIK0001771910
- Category
- Non-accelerated filer<br>Smaller reporting company
- Ticker: Exchange
- ADCT: NYSE
- Fiscal Year End
- December 31
- Owner Organization
- 03 Life Sciences
- SIC
- 2834
- SIC Description
- Pharmaceutical Preparations
- Ticker
- ADCT
SEC filing data through
Insider Sentiment
- Last purchase
- 2024-12-11
- Last sale
- 2026-04-02
- Shares purchased (TTM)
- 0
- Shares sold (TTM)
- 2,529,491
Institutional Sentiment
- As of
- 2026-03-31
- Institutional shares owned
- 82,495,304
- Shares outstanding
- 154,142,347
- Ownership
- 53.52%
Earnings Market Reaction
- Filing date
- 2026-08-13
- Price on filing date
- —
- 1-month reaction
- 29.52%
- 3-month reaction
- Pending
Balance Sheet
Values in millions ($)| Line item | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-12-31 | 2024-09-30 | 2024-06-30 | 2024-03-31 | 2023-12-31 | Subscriber-only column | Subscriber-only column | Subscriber-only column | Subscriber-only column | Subscriber-only column | Trend |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Assets Current | |||||||||||||||||
| Cash And Cash Equivalents At Carrying Value | 219 | 231 | 261 | 235 | 265 | 195 | 251 | 274 | 300 | 234 | 279 | ||||||
| Accounts And Other Receivables Net Current | 28 | 31 | 29 | 23 | 26 | 32 | 20 | 24 | 23 | 23 | 25 | ||||||
| Inventory Net | 5 | 5 | 4 | 18 | 18 | 17 | 2 | 16 | 15 | 16 | 16 | ||||||
| Prepaid Expense And Other Assets Current | 5 | 6 | 6 | 6 | 5 | 7 | 8 | 19 | 17 | 17 | 10 | ||||||
| Other Assets Current | 4 | 4 | 6 | 6 | 6 | 7 | 9 | - | - | - | 6 | ||||||
| Assets Current | 262 | 277 | 306 | 287 | 319 | 258 | 291 | 333 | 355 | 290 | 336 | ||||||
| Inventory Noncurrent | 15 | 12 | 14 | - | - | - | 16 | - | - | - | - | ||||||
| Property Plant And Equipment Net | - | - | 0 | 0 | 0 | 5 | 5 | 6 | 5 | 6 | 6 | ||||||
| Operating Lease Right Of Use Asset | 1 | 1 | 1 | 1 | 1 | 8 | 8 | 9 | 10 | 10 | 11 | ||||||
| Deferred Income Tax Assets Net | - | - | - | - | - | - | - | - | - | - | 0 | ||||||
| Equity Method Investments | - | - | - | - | - | - | 0 | 0 | 0 | 1 | 2 | ||||||
| Other Assets Noncurrent | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | ||||||
| Assets | 279 | 291 | 323 | 290 | 322 | 273 | 322 | 349 | 372 | 308 | 355 | ||||||
Liabilities Current | |||||||||||||||||
| Accounts Payable Current | 13 | 5 | 9 | 8 | 10 | 16 | 18 | 14 | 11 | 14 | 16 | ||||||
| Accrued Liabilities Current | 67 | 58 | 58 | 54 | 55 | 42 | 62 | 53 | 47 | 49 | 52 | ||||||
| Long Term Debt Current | 6 | 5 | 3 | - | - | - | 0 | - | - | - | - | ||||||
| Liabilities Current | 86 | 68 | 70 | 62 | 65 | 58 | 80 | 68 | 58 | 63 | 68 | ||||||
| Operating Lease Liability Current | - | - | - | - | - | - | - | - | - | - | 1 | ||||||
| Secured Long Term Debt | 110 | 111 | 112 | 115 | 114 | 114 | 114 | 114 | 114 | 113 | 113 | ||||||
| Warrants And Rights Outstanding | 4 | 19 | - | - | - | - | - | - | - | - | - | ||||||
| Operating Lease Liability Noncurrent | 1 | 1 | 1 | 1 | 1 | 8 | 8 | 9 | 9 | 10 | 10 | ||||||
| Other Liabilities Noncurrent | 6 | 5 | 3 | 9 | 7 | 4 | 2 | 8 | 7 | 7 | 9 | ||||||
| Liabilities | 508 | 508 | 509 | 528 | 521 | 511 | 525 | 521 | 503 | 502 | 503 | ||||||
Stockholders Equity Including Portion Attributable To Noncontrolling Interest | |||||||||||||||||
| Common Stock Value | 11 | 11 | 11 | 10 | 10 | 8 | 8 | 8 | 8 | 7 | 7 | ||||||
| Additional Paid In Capital | 1,447 | 1,442 | 1,440 | 1,382 | 1,380 | 1,287 | 1,284 | 1,282 | 1,279 | 1,181 | 1,181 | ||||||
| Treasury Stock Value | -0 | -0 | -0 | -0 | -0 | -0 | -0 | -0 | -0 | -1 | -1 | ||||||
| Accumulated Other Comprehensive Income Loss Net Of Tax | -1 | -1 | -1 | -1 | -0 | -1 | -1 | 0 | -0 | -0 | -0 | ||||||
| Retained Earnings Accumulated Deficit | -1,685 | -1,669 | -1,636 | -1,630 | -1,589 | -1,532 | -1,493 | -1,463 | -1,419 | -1,382 | -1,335 | ||||||
| Stockholders Equity | -228 | -216 | -186 | -238 | -199 | -238 | -203 | -172 | -132 | -194 | -148 | ||||||
| Liabilities And Stockholders Equity | 279 | 291 | 323 | 290 | 322 | 273 | 322 | 349 | 372 | 308 | 355 | ||||||
| Common Stock Par Or Stated Value Per Share | 0.08 | 0.08 | 0.08 | 0.08 | 0.08 | 0.08 | 0.08 | 0.08 | 0.08 | 0.08 | 0.08 | ||||||
| Common Stock Shares Issued | 130 | 130 | 128 | 115 | 115 | 102 | 102 | 99 | 99 | 89 | 89 | ||||||
| Shares Outstanding | 127 | 127 | 126 | 113 | 112 | 99 | 99 | 97 | 96 | 83 | 82 | ||||||
| Treasury Stock Common Shares | 3 | 3 | 3 | 3 | 3 | 3 | 3 | 3 | 3 | 6 | 7 | ||||||
Select a line item above to chart it.
Recent filings
- 10-QFiled
- 10-QFiled
- 10-KFiled
- 10-QFiled
- 10-QFiled
- 10-QFiled
- 10-KFiled
- 10-QFiled
- 10-QFiled
- 10-QFiled
- 10-KFiled
Financial statements beyond 3 years are for subscribers only.
Unlock 17+ years of income statements, balance sheets, and cash flow statements
Start 7-day free trialADC Therapeutics SA (ADCT) — SEC Financial Statements & Analysis
ADC Therapeutics SA (ADCT) is a pharmaceutical preparations company, incorporated in V8. ADC Therapeutics SA trades on NYSE as: ADCT. ADC Therapeutics SA (ADCT)'s most recent SEC filing is a Form 10-Q for the period ended 2026-06-30, filed with the SEC on 2026-08-13. Based on that filing, ADC Therapeutics SA carries a market cap of $165.87M, a P/E ratio of -1.71x, a P/B ratio of -0.73x, a P/S ratio of 1.94x, an enterprise value of $63.38M, and an EV/EBITDA multiple of -0.64x. On profitability, it posts an operating margin of -116.63%, a net margin of -113.54%, a Return on Equity (ROE) of 45.35%, and a Return on Assets (ROA) of -32.25%. Per share, it reports EPS of $-0.63, diluted EPS of $-0.63, free cash flow per share of $-0.66, and a dividend per share of $0.00. Over the trailing year, it posted revenue growth of 19.81% year-over-year, net income growth of -42.98% year-over-year, and EPS growth of -58.16% year-over-year. On the balance sheet, it maintains a current ratio of 3.03x, a quick ratio of 2.91x, working capital of $175.38M, a debt-to-equity ratio of -2.22x, a debt ratio of 1.82, an interest coverage ratio of -1.90x, free cash flow of $-102.30M (TTM), and net debt of $-102.49M. Figures sourced from SEC EDGAR.
- Market Cap
- $165.87M
- P/E TTM
- -1.71x
- EPS TTM
- $-0.63
- P/B TTM
- -0.73x
- ROE TTM
- 45.35%
- ROA TTM
- -32.25%
- Debt To Equity
- -2.22x
- Free Cash Flow TTM
- $-102.30M
- Net Revenue TTM Growth 1Y
- 19.81%
Data as of 2026-06-30 · Source: SEC EDGAR
Frequently Asked Questions
What industry is ADC Therapeutics SA in?
ADC Therapeutics SA (ADCT) operates in the Pharmaceutical Preparations industry.
What exchange does ADCT trade on?
ADC Therapeutics SA (ADCT) trades on the NYSE.
Where is ADC Therapeutics SA incorporated?
ADC Therapeutics SA is incorporated in Switzerland.
When was ADC Therapeutics SA (ADCT)'s most recent SEC filing?
ADC Therapeutics SA (ADCT)'s most recent SEC filing is a Form 10-Q for the period ended 2026-06-30, filed with the SEC on 2026-08-13.
What is ADCT's market cap?
ADC Therapeutics SA (ADCT) has a market capitalization of $165.87M as of 2026-06-30.
What is ADCT's EPS (earnings per share)?
ADC Therapeutics SA (ADCT)'s trailing twelve month EPS is $-0.63 as of 2026-06-30.
What is ADCT's ROE (return on equity)?
ADC Therapeutics SA (ADCT)'s trailing twelve month Return on Equity (ROE) is 45.35% as of 2026-06-30.
What is ADCT's ROA (return on assets)?
ADC Therapeutics SA (ADCT)'s trailing twelve month Return on Assets (ROA) is -32.25% as of 2026-06-30.
What is ADCT's EV/EBITDA?
ADC Therapeutics SA (ADCT)'s trailing twelve month EV/EBITDA is -0.64x as of 2026-06-30.